Zimmer Partners’s CG Oncology CGON Stock Holding History

Zimmer Partners’s Portfolio CGON Stock Details CGON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10,000	Closed	-$287K	–	183
2024 Q4	$287K	Buy	+10,000	New	+$342K	﹤0.01%	146

Other funds holding CGON

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

FCMV

Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return

Zimmer Partners's CGON Position: Q1 2025 in Review

Zimmer Partners sold out of CG Oncology (CGON) in Q1 2025, closing a stake of 10,000 shares — an estimated $287K sold.

Zimmer Partners first reported a position in CGON in Q4 2024 and held it in 1 quarter. The position peaked at $287K in Q4 2024. 142 funds tracked by Wall St. Rank hold CGON as of Q1 2025.

Zimmer Partners reported no remaining CG Oncology position as of Q1 2025 after selling out during the quarter.
Zimmer Partners sold 10,000 CG Oncology shares in Q1 2025, an estimated $287K.
Zimmer Partners first reported a position in CG Oncology in Q4 2024 and held it in 1 quarter.
Zimmer Partners's CG Oncology position peaked at $287K in Q4 2024.
142 funds tracked by Wall St. Rank held CG Oncology as of Q1 2025.

Based on Zimmer Partners's 13F filing for Q1 2025, filed 15 May 2025.